<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>L-asparaginase is commonly used in the chemotherapy regimens for <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Its use is associated with thrombotic complications in 1 to 14 % of the cases </plain></SENT>
<SENT sid="2" pm="."><plain>The pathogenesis of this complication is still unclear </plain></SENT>
<SENT sid="3" pm="."><plain>However, the decrease of antithrombin seems to play an important role </plain></SENT>
<SENT sid="4" pm="."><plain>We report a case of a 17-year old man with a <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>, who developed a cerebral sinovenous <z:mp ids='MP_0005048'>thrombosis</z:mp> due to an acquired deficiency of antithrombin and protein C and S following L-asparaginase chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>We discuss the use of prophylactic supplements of antithrombin and the value of screening of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> based on the recent medical literature </plain></SENT>
</text></document>